Conestat alfa

Drug Profile

Conestat alfa

Alternative Names: Human C1 esterase inhibitor - Pharming; Recombinant human C1 esterase inhibitor - Pharming; rhC1INH; Rhucin; Ruconest

Latest Information Update: 22 Nov 2016

Price : $50

At a glance

  • Originator Pharming Group NV
  • Class Complement C1 inactivator proteins; Immunotherapies; Recombinant proteins; Vascular disorder therapies
  • Mechanism of Action Complement C1r inhibitors; Complement C1s inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hereditary angioedema; Delayed graft function; Capillary leak syndrome
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hereditary angioedema
  • Preclinical Delayed graft function; Reperfusion injury
  • Discontinued Renal transplant rejection

Most Recent Events

  • 14 Nov 2016 Launched for Hereditary angioedema in South Korea before November 2016 (IV)
  • 14 Nov 2016 Launched for Hereditary angioedema in Venezuela, Panama, Dominican Republic, Costa Rica, Colombia, Argentina, Yemen, United Arab Emirates, Tunisia, Syria, Switzerland, Spain, Qatar, Oman, Morocco, Luxembourg, Lebanon, Kuwait, Jordan, Belgium, Bahrain, Andorra, Algeria before November 2016 (IV)
  • 11 Nov 2016 Committee for Medicinal Products for Human Use (CHMP) recommends an extension to the terms of marketing authorisation of Ruconest® for the treatment of Hereditary angioedema in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top